Canadian Public Reimbursement of Subsequent Entry Biologics (Sebs) / Biosimilars
نویسندگان
چکیده
منابع مشابه
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.
*Authors who contributed equally 1Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta; 2University of British Columbia, Vancouver, British Columbia; 3IBD Clinical and Research Centre and Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba; 4Division of Gastroenterology, University of Alberta, Edmonton, A...
متن کاملSubsequent Entry Biologics in Canada: Current State of the Science.
The Canadian Society for Pharmaceutical Sciences organized a workshop on the current state of sciences of subsequent entry biologics (SEBs, biosimilars) on December 10th 2014 in the Health Canada location in Ottawa, ON. The day-long workshop provided an opportunity to discuss recent regulatory developments and a wide range of scientific issues related to SEBs. Following a discussion on the diff...
متن کاملHealth Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.
In May 2012, Health Canada and other participants held a National Summit on Subsequent Entry Biologics (SEBs). Health Canada released a guidance document in March 2010 describing policy positions and data requirements for approval of SEBs. While Health Canada and health agencies in other regulatory jurisdictions are aligned on many scientific principles related to biosimilar drugs, Health Canad...
متن کاملUse of Biologics and Biosimilars in Rheumatology.
Prior to the availability of biologics, synthetic DMARDs (Disease modifying anti-rheumatic drugs) were the mainstay of the treatment in rheumatology. With the introduction of biologics, the scenario is changing to become more promising. These drugs have innovative mechanism of action, based on the targeted inhibition of specific molecular or cellular targets directly involved in disease pathoge...
متن کاملBiologics and biosimilars: what, why and how?
1Division of Clinical Pharmacology, Department of Medicine and Therapeutics Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong 2Clinical Research Management Office, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong 3Department of Clinical Oncology at the Sir YK Pao Centre for Cancer Hong Ko...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2015
ISSN: 1098-3015
DOI: 10.1016/j.jval.2015.03.974